PMID- 28203042
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 0918-5739 (Print)
IS  - 1347-7358 (Electronic)
IS  - 0918-5739 (Linking)
VI  - 26
IP  - 1
DP  - 2017 Jan
TI  - Relationship between dose of antithyroid drugs and adverse events in pediatric 
      patients with Graves' disease.
PG  - 1-7
LID - 10.1297/cpe.26.1 [doi]
AB  - Graves' disease (GD) accounts for a large proportion of pediatric 
      hyperthyroidism, and the first-line treatment is antithyroid drug (ATD) therapy. 
      Methimazole (MMI) is effective in most patients but is associated with 
      significant adverse events (AEs). We reviewed the medical records of GD patients 
      (n = 56) with onset age of <15 yr and investigated the relationship between MMI 
      dose and AEs. The study population comprised 11 male and 45 female patients and 
      the median age at diagnosis was 11 yr. All patients were initially treated with 
      ATDs. Among the 52 patients initially treated with MMI, 20 received a low dose, 
      and 32 received a high dose of MMI (< 0.7 vs >/= 0.7 mg/kg/day, respectively). AEs 
      occurred in 20% of the patients in the low-dose MMI group, and in 50% patients in 
      the high-dose MMI group (p = 0.031). A greater variety of AEs was observed in the 
      high-dose group. Neutropenia and rash were observed in both groups. With 
      treatment transition to low-dose MMI according to the Japanese Society for 
      Pediatric Endocrinology guidelines, we expect a decrease in the incidence of AEs 
      in future. However, we should be careful as neutropenia and rash can occur 
      independently of the MMI dose.
FAU - Yasuda, Kie
AU  - Yasuda K
AD  - Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, 
      Japan.
FAU - Miyoshi, Yoko
AU  - Miyoshi Y
AD  - Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, 
      Japan.
FAU - Tachibana, Makiko
AU  - Tachibana M
AD  - Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, 
      Japan.
FAU - Namba, Noriyuki
AU  - Namba N
AD  - Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, 
      Japan; Department of Pediatrics, Japan Community Health Care Organization Osaka 
      Hospital, Osaka, Japan.
FAU - Miki, Kazunori
AU  - Miki K
AD  - Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, 
      Japan; Department of Pediatrics, Itami Municipal Hospital, Hyogo, Japan.
FAU - Nakata, Yukiko
AU  - Nakata Y
AD  - Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 
      Osaka, Japan.
FAU - Takano, Toru
AU  - Takano T
AD  - Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 
      Osaka, Japan.
FAU - Ozono, Keiichi
AU  - Ozono K
AD  - Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20170131
PL  - Japan
TA  - Clin Pediatr Endocrinol
JT  - Clinical pediatric endocrinology : case reports and clinical investigations : 
      official journal of the Japanese Society for Pediatric Endocrinology
JID - 9433330
PMC - PMC5295245
OTO - NOTNLM
OT  - Graves' disease
OT  - adverse event
OT  - antithyroid drug
OT  - children
OT  - methimazole
EDAT- 2017/02/17 06:00
MHDA- 2017/02/17 06:01
PMCR- 2017/01/01
CRDT- 2017/02/17 06:00
PHST- 2016/05/23 00:00 [received]
PHST- 2016/11/22 00:00 [accepted]
PHST- 2017/02/17 06:00 [entrez]
PHST- 2017/02/17 06:00 [pubmed]
PHST- 2017/02/17 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - 2016-0016 [pii]
AID - 10.1297/cpe.26.1 [doi]
PST - ppublish
SO  - Clin Pediatr Endocrinol. 2017 Jan;26(1):1-7. doi: 10.1297/cpe.26.1. Epub 2017 Jan 
      31.